Particularly, the activation of mGluR1/5 by agonist treatment produces abnormal glutamate release, thus causing glutamate excitotoxicity in a mouse model of ALS [23], whereas the reduction in mGluR1 expression revealed prolonged survival probability, delayed pathology onset, and slower disease progression [24]. Here, GRM1 is linked to amyotrophic lateral sclerosis.